Company / Debt per Share
Viridian Therapeutics, Inc.\DE Debt per Share History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$0.25
FY2024
5-year range
$0.00 / $0.45
FY2020-FY2024
Trend
-43.7%
vs FY2023
Sector context
#73 of 82
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's debt per share of $0.25 is lower than 89% of companies in the Health Care sector (FY2024). Debt per Share has fluctuated over the past 7 years, ranging from $0.00 in FY2021 to $11.99 in FY2017.
Based on SEC 10-K filings.
0.25 in FY2024 with a 5-year CAGR of -41.4%.
Increased from $0.14 to $0.25 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -41.4%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 82This company $0.25 Sector average $151.59
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2024, debt per share decreased 43.7% year-over-year.
- Ranks #73 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2017.
- Lowest debt per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.25 | -43.7% |
| FY2023 | $0.45 | +211.9% |
| FY2022 | $0.14 | - |
| FY2021 | $0.00 | - |
| FY2020 | - | - |
| FY2019 | $3.67 | +986.3% |
| FY2018 | $0.34 | -97.2% |
| FY2017 | $11.99 | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026